Redeye comments on the real-world data from Spain and Italy, which demonstrated meaningful objective...
Redeye returns with an updated view following Elicera’s Q2 report and encouraging data from the phas...
Redeye is only making minor changes to our forecasts following the Q2 report and other recent events...
Taaleri will host its CMD tomorrow on Tuesday 2nd of September.
Redeye provides a research update following IRLAB's Q2 report.
Redeye provides its initial take on Heliospectra’s Q2results, which beat our expectations on top-li...
Redeye comments on Binero IT’s H1-25 results, which presented mixed figures.
Idag, fredag 29 augusti, offentliggjorde Enrad AB (”Enrad” eller ”Bolaget”) sin rapport för kv2 2025...
Redeye provides its initial take on Heliospectra’s Q2results, which beat our expectations on top-lin...
Redeye provides an update following Jumpgate’s Q1 2025 report.
Stayble Therapeutics redovisade ingen nettoomsättning och en minskad rörelseförlust under det andra ...
Cereno Scientific’s Q225 results demonstrated steady progress across its clinical assets, with encou...
In Q2, Prolight reported initial positive data from its ongoing whole blood study at St Thomas’ Hosp...
Redeye comments on Lytix Biopharma’s Q2 report 2025 in an extended update.
Redeye comments on FluoGuide’s Q2 2025 report. The company’s recent progress update mostly aligned w...
